您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Letrozole-d4
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Letrozole-d4
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Letrozole-d4图片
CAS NO:1133712-96-5
包装与价格:
包装价格(元)
500 μg电议
1mg电议

产品介绍
来曲唑-d4(CGS 20267-d4)是氘标记的来曲唑。 Letrozole (CGS 20267) 是一种有效的、选择性的、可逆的和口服活性的芳香酶非甾体抑制剂,IC50 为 11.5 nM。来曲唑选择性抑制雌激素的生物合成,可用于乳腺癌的研究。
Cas No.1133712-96-5
别名来曲唑 d4
Canonical SMILES[2H]C(C([2H])=C(C#N)C([2H])=C1[2H])=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3
分子式C17H7D4N5
分子量289.3
溶解度DMF: 16 mg/ml,DMF:PBS (pH 7.2) (1:9): 0.1 mg/ml,DMSO: 16 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Letrozole-d4is intended for use as an internal standard for the quantification of letrozole by GC- or LC-MS. Letrozole is a potent, cell-permeable inhibitor of aromatase (IC50= 2 nM).1It inhibits proliferation of estrogen receptor-positive (ER+) MCF-7 cells when used alone at concentrations ranging from 0.1 to 100 nM and when used at a concentration of 10 nM in combination with testosterone or 4-androstene-3,17-dione.2It also reduces matrix metalloproteinase-2 (MMP-2) and MMP-9 levels in MCF-7 cells when used at a concentration of 10 nM. Letrozole (10 µg per day) reduces tumor growth in an MCF-7Ca ovariectomized-mouse xenograft model.3Formulations containing letrozole have been used in the treatment of postmenopausal breast cancer.4

1.Mayhoub, A.S., Marler, L., Kondratyuk, T.P., et al.Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrolBioorg. Med. Chem.20(7)2427-2434(2012) 2.Mitropoulou, T.N., Tzanakakis, G.N., Kletsas, D., et al.Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cellsInt. J. Cancer104(2)155-160(2003) 3.Long, B.J., Jelovac, D., Handratta, V., et al.Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer modelJ. Natl. Cancer Inst.96(6)456-465(2004) 4.Cohen, M.H., Johnson, J.R., Li, N., et al.Approval summary: Letrozole in the treatment of postmenopausal women with advanced breast cancerClin Cancer Res.8(3)665-669(2002)